Precipio, Inc. (PRPO) Earnings
Precipio, Inc. is expected to report next earnings on November 16, 2026 (in NaN days), with a consensus EPS estimate of $-2.00. PRPO has beaten EPS estimates in 3 of its last 8 reported quarters (average surprise -413.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 17, 2026 | $-2.00 | $-0.12 | +94.0% | $7M | +319.2% |
| Mar 30, 2026 | — | $0.33 | — | $8M | — |
| Nov 14, 2025 | — | $-0.05 | — | $6M | — |
| Aug 13, 2025 | — | $0.05 | — | $6M | — |
| May 14, 2025 | — | $-0.59 | — | $4M | — |
| Mar 27, 2025 | $0.74 | $-0.23 | -131.1% | $5M | -32.0% |
| Aug 13, 2024 | $-0.05 | $-0.83 | -1560.0% | $4M | +2.6% |
| May 14, 2024 | $-0.93 | $-1.46 | -57.0% | $3M | -20.7% |
| Mar 29, 2024 | $-0.93 | $-0.41 | +55.9% | $4M | -0.7% |
| Nov 13, 2023 | $-1.21 | $-1.04 | +14.0% | $4M | -23.7% |
| Aug 11, 2023 | $-0.10 | $-1.80 | -1700.0% | $4M | +30.9% |
| May 12, 2023 | $-0.13 | $-2.60 | -1900.0% | $3M | +270.7% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 17, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Core Business Model & Strategic Advantage - Precipio operates a unique "flywheel" model where the in-house clinical pathology laboratory directly drives product development. The laboratory identifies unmet clinical diagnostic problems firsthand, develops and validates solutions internally, then scales proven solutions to external customers, eliminating common hurdles of developing unproven products for unconfirmed market demand. - This model expands the company's addressable market without requiring new capital to build additional laboratories for new geographies or customers, and creates scalable product revenue alongside core recurring pathology revenue. ### Key Product Development Example: Rapid AML Diagnostic - The company's rapid AML (Acute Myeloid Leukemia) diagnostic test delivers critical time-sensitive results in 1 business day, compared to the industry average of 10-14 days, enabling urgent, appropriate treatment for high-risk patients. - This internally validated solution has garnered significant interest from domestic and international customers; the company is pursuing multiple large marketing collaborations and clinical study initiatives to drive awareness and adoption, which it now has the internal resources to support after years of building infrastructure. ### Q2 2026 Operational & Commercial Progress - The commercial team added 10 new distributed sales representatives in Q2, expanding into new territories and adding over 25 new qualified potential customers, with over 30 customer meetings completed or scheduled, growing the commercial pipeline significantly. - The company has established full market coverage through distribution partnerships with Dillman Fisher, McKesson, Medline, and Cardinal; the commercial team has made progress building customized working relationships with each large distributor, which have differing internal structures, vendor interaction processes, and incentive schemes, overcoming prior ramping challenges. ### Q2 2026 Financial Highlights - Adjusted EBITDA was positive $400,000, a $600,000 sequential improvement from negative $200,000 in Q1 2026, driven by $300,000 in higher revenue and a $200,000 decrease in stock-based compensation. - Generated $700,000 in operating cash flow (equal to 10% of total quarterly revenue), increasing total cash on hand by $500,000 to end the quarter at over $3 million, all generated organically from operations with no new capital raising.
Guidance
- Management expects continued total revenue growth building on the Q2 milestone of exceeding $7 million in quarterly revenue - Product revenue growth is a key focus for the second half of 2026, with continued work to expand the customer base and commercial reach of the product business - Management expects the expanded sales capacity investments made in the first half of 2026 will translate to meaningful conversion of the growing commercial pipeline into active revenue-generating accounts in the second half of 2026 - The company will continue to focus on capturing operating leverage from its existing built-out infrastructure, translating revenue growth into improved adjusted EBITDA and increased organic cash generation - Management reaffirms that the underlying business is on a positive growth trajectory, and the company enters the second half of 2026 in its strongest position to date
Segment performance
Total Q2 2026 revenue was $7 million, a 22% year-over-year increase from $5.7 million in Q2 2025, and a $0.3 million sequential increase from $6.7 million in Q1 2026. 1. Pathology segment: Generated $6.1 million in revenue, representing ~87.1% of total Q2 revenue. This was a modest sequential increase from $6 million in Q1 2026. 2. Product segment: Generated $900,000 in revenue, representing ~12.9% of total Q2 revenue. This was a 35% sequential increase from $660,000 in Q1 2026, and 21% above the company's previous product revenue record of $750,000 set in Q4 2025.
Risks & headwinds
- Forward-looking statements are inherently uncertain, and actual results may differ materially from expectations due to a range of risks, which are detailed in the company's annual Form 3K for the year ended December 31, 2025 and subsequent SEC filings - Quarter-to-quarter revenue variability is expected, particularly in the product segment, due to timing of customer shipments and arbitrary quarterly calendar cutoffs that do not always align with natural business flow - Ramping product revenue through large distributor partners has taken longer than initially expected due to the need to develop customized working relationships for each distributor's unique operating structure
Analyst Q&A
Q: The company saw unusually high trading volume of roughly 800,000 shares over a two-day period last month. Can management explain where this trading activity came from and if the company is aware of the cause?
A: Management does not have additional transparency into the specific source of the trading activity, and the volume spike was just as surprising to management as it was to market participants. Management attributes the increased attention to the company's ongoing investor relations activities, including participation in investment conferences such as the MicroCat Conference in Las Vegas in June, which has increased market awareness of the company as planned at the start of the year. Management also notes that computer algorithmic trading, which is difficult to trace or explain, was likely a contributing factor to the unusual spike in trading volume.